jiliko free 100 no deposit

jiliko free 100 no deposit

Keitenn Bristow scores 23 as Tarleton State tops Florida A&M 70-60What is the Federal Reserve for, exactly, besides bailouts?

BJT pick wins Surin PAO pollDried Tha Khut Pwint produced from Anyar (central Myanmar) has received overseas orders majorly from Thailand and Malaysia. Medicinal dried Hgin Ngout Pwint, also known as Tha Khut Pwint has high consumption and being exported abroad. “It is time that dried Tha Khut Pwint sale is the best among other local foods. Tha Khut Pwint blossoms in monsoon but there are traders who have stocked them. We export it to Yangon as well as overseas, especially Thailand and Malaysia. Tha Khut Pwint can be eaten by cooked or made salad. It is medicinal and it is one of most-consumed food of Anyar,” said an official from Shwe Nyar Thu Anyar-produced foods distribution in Magway Township. Tha Khut Pwint is mainly produced from dry zone such as Magway and Taungdwingyi townships and the price gets slightly high now compared to last monsoon. “In local market, Yangon is the biggest buyer but we don’t have much orders from Mandalay. The price fell in monsoon when they blossomed and now slightly gets high,” he added. – Thit Taw/ZS

In a bold move, Australia announced a world-leading ban on under-16s accessing social media platforms, intending to set a new standard for digital age verification. Prime Minister Anthony Albanese outlined plans for platforms like Instagram and TikTok to implement stringent age-check procedures, possibly using biometrics or government IDs. The proposed legislation, presented in parliament, mandates the destruction of personal data used for age verification, securing citizens' privacy. Critics, including Elon Musk, argue this could serve as a governmental control mechanism over internet access. Despite this, Albanese assured that privacy requirements will be robust. Australia aims to enforce this law by the end of the year, with severe penalties for non-compliance. The measures, which include no parental consent or pre-existing account exemptions, mark one of the toughest stances on social media age restrictions globally, setting potential fines of up to $32 million. (With inputs from agencies.)Ustby, Donarski lead No. 16 North Carolina women over Villanova 53-36 in Battle 4 Atlantis semifinalLocals urged to deepen their understanding of Barbados’ history and heritage

California Water Service Group Named One of “America’s Most Responsible Companies” by Newsweek for Fourth Consecutive YearIND vs AUS 2nd Test of Border-Gavaskar Trophy 2024-25 in Adelaide Registers Record of Fewest Balls Bowled in a Test Match Between India and Australia

CHICAGO (AP) — Blackhawks defenseman Alec Martinez and forward Craig Smith could return in time for the NHL Winter Classic. Martinez and Smith participated in the team's optional morning skate ahead of Sunday night's 5-1 loss to the Dallas Stars. Martinez was placed on injured reserve on Dec. 13 because of a neck injury, and Smith went on IR on Dec. 20 with a back injury. Interim coach Anders Sorensen described Martinez and Smith as day to day. “They're close,” Sorensen said. Martinez and Smith signed with Chicago in free agency last summer. Martinez has one goal and three assists in 15 games, and Smith has six goals and four assists in 26 games. The Blackhawks host the St. Louis Blues on Tuesday in the Winter Classic at Wrigley Field — home of baseball's Chicago Cubs. The Blackhawks shuffled their defensemen ahead of their matchup with Dallas, recalling Wyatt Kaiser from Rockford and assigning Kevin Korchinski to their American Hockey League affiliate. The 20-year-old Korchinski, who was selected by Chicago with the No. 7 pick in the 2022 draft, had five goals and 10 assists in 76 games with the Blackhawks last season. He was brought up by Chicago on Dec. 8 and skated in nine games before he was sent back down. “If you look at his overall development, throughout the season, he’s taken big steps forward in his development,” Sorensen said. “We saw flashes of that early when he was up here and we want to make sure he stays on that track.” AP NHL: https://www.apnews.com/hub/NHLEast Carolina cornerback Shavon Revel Jr., a potential first-round pick, declared for the 2025 NFL Draft on Friday. Revel, who sustained a torn left ACL in practice in September, had one season of eligibility remaining. "After an incredible journey at East Carolina, I am officially declaring for the 2025 NFL Draft," the senior posted on social media. "... Pirates nation, thank you for your unwavering energy and support every game. Representing ECU is an honor, and I look forward to continuing to do so on Sundays!" Revel recorded two interceptions in three games this season, returning one 50 yards for a touchdown on Sept. 14 against Appalachian State. Over three seasons with the Pirates, Revel had three interceptions, 15 passes defensed and 70 tackles in 24 games. He was a second-team All-American Athletic Conference selection last season. ESPN draft analyst Mel Kiper Jr. ranked Revel as the No. 2 cornerback and No. 23 overall prospect in the 2025 draft class. --Field Level Media, which successfully brought a messenger RNA (mRNA)-based COVID-19 vaccine to market, sought twice this past week to reassure investors that it could not only survive but thrive even if Robert F. Kennedy Jr. were to become Secretary of Health and Human Services (HHS) in Donald Trump’s second administration—comments that helped spark a in the company’s stock. At an investor lunch held by Goldman Sachs, and a fireside chat held a few days later by Jefferies, Moderna’s top executives laid out a similar hopeful scenario for why they believe the company will be able to carry out the comeback plans it first announced in September and continue its development of mRNA-based vaccines should Kennedy come to oversee HHS. Moderna CEO Stéphane Bancel and president Stephen Hoge (joined at the event by Lavina Talukdar, the company’s senior vice president and head of investor relations) based their optimism in part on the historic administrative relationship between HHS and its secretaries. “Management highlighted that, according to legislation, the Secretary of the Department of Health and Human Services (HHS) is responsible for managing the department rather than creating policy,” the Moderna leaders asserted, according to a report by Benzinga based on a Morgan Stanley analyst’s account of the lunch. The leaders also reportedly asserted, “It remains uncertain how political appointees might affect the current vaccine regulatory framework, which Moderna believes would require significant effort to alter.” While Kennedy has previously raised concerns about vaccine safety, the concerns focused on vaccines for children; Moderna’s vaccines are not specifically targeted for children. During the luncheon, Bancel and Hoge “expressed strong confidence” in the comeback strategy they laid out for Moderna in September at its annual R&D Day. Moderna committed to stepping up the development of vaccines for cancer and rare diseases, while dialing back investment in infectious disease jabs. Moderna’s strategy jolted investors enough to send shares over the two days following the announcement, to $68.28 on September 13 from $79.51. That’s because the company pushed back by two years, from 2026 to 2028, its plans to break even on an operating cash cost basis—which excludes stock-based compensation, depreciation, and amortization expense—with $6 billion in revenue. Moderna also revealed plans to slash between $1 billion and $1.2 billion in expenses by shrinking its R&D budget by about 20%, from the $4.8 billion it anticipated spending this year to between $3.6 billion and $3.8 billion by 2027. However, last month, Moderna surprised analysts by reporting net income of $13 million (up from a $3.63 billion net loss in Q3 2023) and higher-than-expected sales of its COVID-19 vaccine Spikevax® ($1.8 billion). Yet the unexpected profit wasn’t enough to stave off a drop in Moderna shares. This past week saw better stock news for Moderna, as shares from last week, rising to $41.11 Friday, from $36.85 on November 15. That low (just $1.05 or 3% above the stock’s 52-week low) followed Wolfe Research initiating coverage of Moderna with analyst Alexandria Hammond rating the stock an “Underperform” and setting a 12-month price target of $40. One likely factor in Moderna’s comeback: HSBC analyst Yifeng Liu on November 18 upgraded the firm’s rating on the company’s shares from “Hold” to “Buy.” However, Liu chopped the firm’s price target on Moderna by 29%, from $82 to $58, citing concerns over the company’s comeback plans, according to TipRanks. Despite this week’s relatively good news, Moderna shares are , having closed at $78.17 on November 22, 2023, no small factor in the company mapping out its comeback. But the stock has upside potential, he added, should Moderna deliver on plans to bring 10 pipeline candidates to approvals, up from the current two (SpikeVax and respiratory syncytial virus [RSV] vaccine mRESVIA, the latter approved in May). The 10 include three of Moderna’s five respiratory vaccines with positive Phase III results, which the company expects to submit for approval this year. On Thursday, Jefferies equity analyst Michael J. Yee reported highlights of its fireside chat with unnamed Moderna “management” leaders to investors. Summarizing the event, Yee wrote that the “co[mpany] believes RFK may have caused investor nervousness but unlikely doing anything draconian or removing vaccines.” That belief is based on RFK Jr. asserting in numerous interviews, including , that: “Of course, we’re not going to take vaccines away from anybody,” and, “We are going to make sure that Americans have good information about vaccines and vaccine safety.” Moderna’s view was buttressed by comments made in a separate Jeffries fireside chat with Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research (CBRE). According to Yee, Marks “doesn’t expect any changes to vaccine approvals + the new admin’s stance has mostly been around vaccine mandates [FDA only weighs in on safety/efficacy].” He expects “add’l AdComm’s [advisory committee meetings on applications for new vaccines] or other pushes for transparency would be an oppt’y to reinforce + shift dialogue towards risk benefit.” In a separate summary elaborating on Marks’ comments, Yee reported: “Dr. Marks stated that ‘he isn’t going anywhere’ and sees it as imp’t [important] that people see constant and consistent leadership—FDA leadership has a long track record of working w/ different admins including the Trump admin[instration].” Marks cited FDA cooperation with Operation Warp Speed initiative, through which Trump’s first administration shepherded development of COVID-19 vaccines through funding of trials and manufacturing. According to a , Operation Warp Speed spent over $18 billion dollars of U.S. public funds on six vaccine candidates, including Moderna’s SpikeVax, the subject of a to manufacture and deliver 100 million doses. “While acknowledging uncertainty and that he can’t fully predict workforce impacts, his belief is that the vast majority at FDA generally have very strong relationships w/ their management and leadership and a commitment to unmet needs and rare diseases which wouldn’t change under a new admin,” Yee added. At HHS, Kennedy would oversee agencies that include the FDA—for which Trump said Friday he plans to nominate Marty Makary, MD, as commissioner—and the U.S. Centers for Disease Control and Prevention (CDC), for which Dave Weldon, MD, a physician and former Republican Congressman from Florida, will be nominated as director. Moderna leaders also told Jefferies that they projected COVID-19 vaccines revenues averaging $2 billion to $3 billion annually, Yee reported, a “durable base biz [business] given vaccination data from the last 2 years in the ‘endemic’ commercial market.” The company reasoned that because COVID-19 vaccines are not now mandated, “people who are opting to receive the jab should con’t [continue] to do so year over year.” Two pioneers in artificial intelligence (AI)-based drug development became one this past week when and Exscientia they said would help them fulfill commitments to deliver first-in-class and best-in-class drug discovery. However, a pair of analysts took a more cautious view of the companies joining forces. Mani Foroohar, MD, of Leerink Partners acknowledged two benefits of the combination deal: It extends Recursion’s cash runway into 2027 and provides the company with additional tools in Exscientia’s pipeline candidates, as well as its precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform. “We see long-term risks associated with pipeline prioritization and deal execution,” Foroohar cautioned, citing the companies’ plan to generate annual savings through operational “synergies’ of $100 million. Those synergies included job cuts, Najat Khan, PhD, Recursion’s chief R&D officer and chief commercial officer, . The combined workforce has shrunk from about 900 pre-combination to approximately 800. Foroohar also cited Recursion’s delayed timing for several of its pipeline candidates: The company also deprioritized a second program for a fourth candidate, in advanced AXIN1/APC-mutant cancers. The combined company, which assumed the Recursion name and stock ticker (Exscientia’s ticker of NASDAQ: EXAI has ceased trading and has been delisted), is a trans-Atlantic AI powerhouse with a pipeline of more than 10 clinical and preclinical programs, 10 programs in advanced discovery phases, and more than 10 additional programs partnered with biopharmas. Recursion CEO Chris Gibson, PhD, who keeps his position in the combined company, has envisioned growing to . “Investors continue to struggle with the abundance of programs for a company with a heavy cash burn,” Foroohar commented. “In light of this dynamic, we would advocate a more disciplined and focused approach with aggressive headcount and pipeline rationalization.” Investor reaction appeared to reflect the caution voiced by Foroohar. Shares of the newly-combined Recursion the day the combination took effect Thursday, from $6.04 to $5.75, and Friday, to $5.70. In the months leading up to the combination, the stock yo-yoed from $6.84 on August 8, peaking at $7.84 on November 11 before retreating. Foroohar reiterated Leerink’s “Market Perform” rating and $8 price target on Recursion shares. Also staying in place was Needham analyst Gil Blum, PhD, who reiterated his firm’s “Buy” rating and $11 price target. Dennis Ding, equity analyst with Jefferies, wrote in a research note that the company could generate a potential $50 million in cost savings next year alone from shrinking its real estate footprint, reducing its spending on external contract research, and consolidating its late discovery stage pipeline programs. He projected Recursion will offer more information on cost-cutting when it reports fourth quarter 2024 results early in the new year. On the value creation side, however, Ding said Recursion’s stock could see a boost if it reports positive data next month from its lead cancer candidate REC-617 (formerly GTAEXS617), an Exscientia-developed CDK7 inhibitor being developed to treat advanced solid tumors. Recursion expects to report initial monotherapy safety and pharmacokinetic and pharmacodynamic (PK/PD) data from the Phase I portion of the Exscientia-initiated Phase I/II ELUCIDATE trial ( ) on December 9 during the American Association for Cancer Research (AACR) Special Conference, being held in Toronto, and the following day at a webinar. “We think this is the next catalyst for the stock and coming up imminently,” Ding declared. In a September , Exscientia said preclinical models suggested 8-10 hours of IC [in vitro 80% inhibitory] coverage on CDK7 was optimal, while less coverage compromised efficacy and longer coverage could result in signals of safety problems. “The therapeutic window is very narrow for CDK7, and—outside of obvious chemical design choices—RXRX hopes to have a short half-life ~6-8 hours to hit CDK7 hard but not long enough to drive tox[icity],” Ding observed. “It’s imperative they thread the needle on this.”Mayfield sparks Bucs with 'Double Tommy tribute'

Super Micro Computer 's stock soared more than 30% on Nov. 19 after it appointed a new independent auditor and submitted a compliance plan to Nasdaq to avoid a potential delisting. Those announcements addressed its two pressing issues: the departure of its auditor Ernst & Young in October, and a delayed filing for its 10-K report, which could cause its stock to be delisted. But even after that rally, Supermicro's stock remains 76% below its all-time high from this March. The server maker's shares are still being weighed down by concerns about its sliding gross margins, competition from bigger server makers like Dell Technologies and Hewlett Packard Enterprise , and troubling allegations of inflated revenues from a prolific short seller. Its delayed annual report and loss of Ernst & Young seemed to support that bearish thesis, and the Department of Justice (DOJ) is reportedly getting ready to probe Supermicro's business. Supermicro's stock looks dirt cheap at 8 times forward earnings , but it will likely trade at that discount until it fully resolves its accounting and regulatory issues. So instead of betting on Supermicro's long-shot turnaround, investors would probably be better off sticking with these two millionaire-maker blue chip AI stocks instead: Microsoft ( MSFT 1.00% ) and Broadcom ( AVGO 0.18% ) . The AI software leader: Microsoft Microsoft generated a total return of more than 900% over the past decade. That rally, which was mainly driven by the explosive growth of its cloud business, would have turned a $100,000 investment into more than $1 million. Microsoft turned into a growth stock again after Satya Nadella, who became its CEO in 2014, drove the company to transform its desktop-based software into cloud-based services and mobile apps. It also turned Azure into the world's second-largest cloud infrastructure platform and expanded its hardware and gaming businesses. Over the past five years, Microsoft ramped up its investments in OpenAI, the creator of ChatGPT, and integrated the start-up's generative AI tools into its own search and cloud services. Thanks to that foresight, it tethered more businesses and consumers to its cloud ecosystem, and it gained a first-mover's advantage against Alphabet 's Google and other tech giants in the nascent generative AI market. In fiscal 2024 (which ended this June), Microsoft's AI-driven transformation boosted its total cloud revenues by 23% to $135 billion -- which represented 55% of its top line. From fiscal 2024 to fiscal 2027, analysts expect its revenue and earnings per share (EPS) to grow at a compound annual growth rate (CAGR) of 14% and 15%, respectively. Its stock still looks reasonably valued at 28 times next year's earnings, and it will likely remain a top play on the AI market for years to come. The AI chipmaking play: Broadcom Broadcom, which was known as Avago before it took over the original Broadcom in 2016, has generated a total return of 2,300% over the past 10 years. That rally would have turned a $50,000 investment into $1.2 million. Broadcom's semiconductor business sells a broad range of chips for the mobile, wireless, networking, data storage, and industrial markets. But over the past few years, it built a massive infrastructure software business by acquiring CA Technologies, Symantec's enterprise security division, and the cloud software giant VMware. Broadcom's chipmaking and software businesses are both growing. But over the past two years, its sales of networking and optical chips for the AI-oriented data center market skyrocketed as more companies upgraded their infrastructure. For fiscal 2024 (which ended in October), it expects its sales of AI-oriented chips to roughly triple to $12 billion, or nearly a quarter of its projected sales for the full year. That rapid growth should offset its slower sales of non-AI chips and infrastructure software, which are both more sensitive to macro headwinds. From fiscal 2024 to fiscal 2026, analysts expect Broadcom's revenue to grow at a CAGR of 15% as its EPS increases at a CAGR of 124%. That earnings growth should be driven by brisk sales of AI chips and the expansion of its higher-margin software business. Its stock might seem a bit pricey at 42 times forward earnings, but its track record of smart acquisitions, high exposure to the AI market, and robust growth could justify that higher valuation.

Foreign governments, including Russia, Iran, China and Israel, have responded to the fall of Syrian President Bashar al-Assad on Sunday. On Saturday evening and Sunday morning, Syrian rebels streamed into their country's capital of Damascus as the 24-year-old regime of President Assad reportedly collapsed with Reuters reporting that Assad had fled the city. The head of Syria's main opposition group abroad, Hadi al-Bahra, declared that Damascus is now "without Bashar al-Assad." The government evacuated the Damascus airport and halted all flights, according to pro-government radio station Sham FM. In response, several foreign countries are addressing the recent developments and are reaffirming the safety of their citizens in Syria. In a statement on Sunday the foreign ministry of Russia, a key Assad ally, said it was "closely following the dramatic events in Syria" and urged everyone "to refrain from using violence and resolve all issues through political means." It commented: "As a result of negotiations between B. Assad and a number of participants in the armed conflict on the territory of the Syrian Arab Republic, he decided to resign from the presidency and left the country, giving instructions for a peaceful transfer of power. Russia did not participate in these negotiations." In addition, according to the Moscow Times, Senator Konstantin Kosachev said the main priority for Moscow is "to ensure the safety" of Russian citizens in Syria. "For us, as Russians, the primary task is to ensure the safety of our compatriots and civilians, including diplomats and their families,"Kosachev said. Later on Sunday, the Associated Press reported via Russian media that Assad fled to Moscow on Sunday. The Russian agencies, Tass and RIA, cited an unidentified Kremlin source on Assad and his family being given asylum in Moscow, his longtime ally and protector. The Associated Press was not immediately able to verify the reports. Meanwhile, Iran has also responded, in a statement released on Sunday the Iranian Foreign Ministry reaffirmed Iran's policy to respect the unity, national sovereignty and territorial integrity of Syria, according to Tasnim, adding that only Syrians can decide the future of their country. In addition, Esmaeil Baqaei, spokesperson for the Iranian Foreign Ministry, announced on Sunday that they are ensuring the safety and security of the Iranian embassy staffers in Damascus, Tasnim reported. China's foreign ministry said in a statement it "is closely following the development of the situation in Syria and hopes that Syria returns to stability as soon as possible," according to Hong Kong Free Press. "The Chinese government has actively assisted Chinese citizens who are willing to leave Syria in a safe and orderly way and has maintained contact with... Chinese citizens who remain in Syria," the ministry said. It comes after China's ties to Syria have grown in recent years as Chinese President Xi Jinping and Assad announced a "strategic partnership" between their countries during Assad's trip to China in 2023. This is a historic day for the Middle East. The collapse of the Assad regime, the tyranny in Damascus, offers great opportunity but also is fraught with significant dangers. We send a hand of peace to all those beyond our border in Syria: to the Druze, to the Kurds, to the... pic.twitter.com/yJZE3AZZJn Meanwhile, Israeli Prime Minister Benjamin Netanyahu celebrated the fall of al-Assad during a visit to the Israeli controlled Golan Heights, along the border with Syria, on Sunday. According to an Israeli government press release, Netanyahu and his Defense Minister Yisrael Katz received a briefing from Major General Ori Gordin, who heads the Israel Defense Forces' (IDF) northern command, on the latest developments in Syria as Netanyahu said it was "a historic day in the history of the Middle East." He added: "The Assad regime is a central link in Iran's axis of evil—this regime has fallen. This is a direct result of the blows we have inflicted on Iran and Hezbollah, the main supporters of the Assad regime. This has created a chain reaction throughout the Middle East of all those who want to be free from this oppressive and tyrannical regime." Newsweek has reached out to foreign ministries of Russia, Iran, China, and Israel via email for comment. Assad's fall came after his main backers, Russia, Iran and its Lebanese ally Hezbollah, were either distracted or weakened by other conflicts. Since February 2022, Russia has been embroiled in a brutal war against Ukraine, while Hezbollah has suffered severely over the past few months in an Israeli campaign which killed the group's leader Hassan Nasrallah in September . Since the Syrian Civil War erupted in 2011, Israel has periodically carried out airstrikes targeting Iranian aligned militant groups and Iran's Islamic Revolutionary Guard Corps in the country. Israeli jets have also repeatedly targeted what they claimed were arms shipments being moved through Syria to Hezbollah. Meanwhile, following the fall of Damascus, President elect- Donald Trump mentioned several of these countries as he called for a ceasefire between Russia and Ukraine in a post on his Truth Social website. Trump said: "Assad is gone. He has fled his country. His protector, Russia, Russia, Russia, led by Vladimir Putin , was not interested in protecting him any longer. There was no reason for Russia to be there in the first place. They lost all interest in Syria because of Ukraine, where close to 600,000 Russian soldiers lay wounded or dead, in a war that should never have started, and could go on forever." "Russia and Iran are in a weakened state right now, one because of Ukraine and a bad economy, the other because of Israel and its fighting success. Likewise, Zelensky and Ukraine would like to make a deal and stop the madness. They have ridiculously lost 400,000 soldiers, and many more civilians." The president-elect concluded: "There should be an immediate ceasefire and negotiations should begin. Too many lives are being so needlessly wasted, too many families destroyed, and if it keeps going, it can turn into something much bigger, and far worse. I know Vladimir well. This is his time to act. China can help. The World is waiting!" President Joe Biden spoke Sunday at the White House about Assad's fall. "After 13 years of civil war in Syria, more than half a century of brutal authoritarian rule by Bashar al-Assad and his father before him, rebel forces have forced Assad to resign his office, flee the country...At long last the Assad regime has fallen," Biden said.

In the fast-paced world of marketing, Enfection is setting the bar high. Founded in 2017 by Saliya Withana and Lahiru Halkewela, this Sri Lankan tech-driven marketing company is all about blending AI with creativity to take businesses to the next level. Their mission is to bring science and technology to the field of marketing. With an impressive client list that includes MAS, Keells, CBL, and Rocell, Enfection’s impact stretches far beyond Sri Lanka, partnering with global ad networks like Dentsu Singapore, McCann Malaysia, and TBWA. They are all about helping businesses push the envelope through AI-based solutions and performance marketing. The secret to their success is their team that is obsessed with staying ahead of the curve. Whether it is AI marketing, AR, or 3D/CGI technology, Enfection has got it covered. One of their standout offerings is Momentro, a SaaS platform designed to give marketers, agencies, and content creators deep insights into audiences, brand positioning, and buyer intent. It is all about equipping brands with the tools to understand their customers better and create more targeted, effective strategies. On 11 November, they hosted the highly anticipated ‘Change the Convo 2024: Put AI to Work’ event at Courtyard by Marriott Colombo, where they brought together CMOs and marketing heads from Sri Lanka’s largest corporations. The aim was to show these marketing leaders how they can use AI to stay ahead of the competition, improve ROI, and foster long-term innovation. Boston Consulting Group Global AI Marketing Lead Sanjay Nair opened the event with a compelling message about the transformative power of generative AI (Gen AI). Drawing from their extensive experience, they stressed that deploying AI within organisations is not merely a technological endeavour – it is a people-centric journey. He emphasised that positioning Gen AI as a tool for efficiency often raises fears about job security among employees. “It’s crucial to highlight the personal and organisational benefits,” they said, “focusing on how it can make day-to-day tasks more fulfilling, rather than solely as a productivity booster.” His advice underscored the importance of change management, advocating for transparency and clarity in communicating the why behind adopting Gen AI. The ‘Change the Convo 2024’ event was such a dynamic hub of innovation, with standout keynote speakers and panel discussions that explored AI’s impact on the marketing world. Nair kicked things off by outlining a clear roadmap for businesses to adopt AI smoothly. Aeos Labs CEO and Founder Harshavardhan Reddy followed with a deep dive into how AI is transforming everything from design to automation and personalisation in marketing. Enfection CEO and Founder Saliya Withana then shared his vision on building AI-ready teams, focusing on predictive and generative AI tools. The panellists – Asia Pacific COO Jeremy Seow, Ren CEO Rukmal Weerawarana, and Daraz Regional Head of Legal Mahela Liyanage covered hot topics such as ‘AI in PR’, where experts discussed how to manage user sentiment, the evolution of AI in marketing, and the tricky intersection of AI and copyright. It was a day packed with insights, all designed to help marketers get ahead in the AI-powered future. One of the most exciting moments was the launch of the AI Marketing Blueprint, an actionable guide designed to help CMOs and marketing teams navigate their AI journey. It covers everything from data infrastructure to leadership and team building, making it a must-read for anyone serious about transforming their marketing with AI. The event went beyond technical jargon, making AI accessible and engaging through real-world applications. Digital twins and AI-powered humour demonstrated the practical side of AI, blending functionality with entertainment. Interactive elements like QR codes enabled seamless audience participation, fostering a dynamic exchange of ideas and questions. Thematic booths offered hands-on exposure to cutting-edge AI solutions, inspiring attendees with practical innovations ready for immediate application in their own industries.RingCentral to Present at Upcoming Investor Conferences